CN104520304B - 咪唑并[2，1‑b]噻唑衍生物、其制备及作为药物的用途 - Google Patents

咪唑并[2，1‑b]噻唑衍生物、其制备及作为药物的用途 Download PDF

Info

Publication number
CN104520304B
CN104520304B CN201380041504.1A CN201380041504A CN104520304B CN 104520304 B CN104520304 B CN 104520304B CN 201380041504 A CN201380041504 A CN 201380041504A CN 104520304 B CN104520304 B CN 104520304B
Authority
CN
China
Prior art keywords
compound
general formula
compounds
phenylimidazo
maleate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380041504.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN104520304A (zh
Inventor
玛丽亚·德拉斯艾米塔斯·阿尔卡尔德-佩斯
乔斯-路易斯·迪亚斯-费尔南德斯
玛丽亚·德拉斯诺伊斯·梅斯基达-埃斯特韦斯
劳拉·帕洛玛-罗梅乌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ethiway Pharmaceutical Co Ltd
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Publication of CN104520304A publication Critical patent/CN104520304A/zh
Application granted granted Critical
Publication of CN104520304B publication Critical patent/CN104520304B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201380041504.1A 2012-07-04 2013-07-04 咪唑并[2，1‑b]噻唑衍生物、其制备及作为药物的用途 Expired - Fee Related CN104520304B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12382269.4A EP2682395A1 (en) 2012-07-04 2012-07-04 Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments
EP12382269.4 2012-07-04
PCT/EP2013/064113 WO2014006130A1 (en) 2012-07-04 2013-07-04 IMIDAZO[2,1-b]THIAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS

Publications (2)

Publication Number Publication Date
CN104520304A CN104520304A (zh) 2015-04-15
CN104520304B true CN104520304B (zh) 2017-02-22

Family

ID=48741189

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380041504.1A Expired - Fee Related CN104520304B (zh) 2012-07-04 2013-07-04 咪唑并[2，1‑b]噻唑衍生物、其制备及作为药物的用途

Country Status (10)

Country Link
US (1) US9617281B2 (enExample)
EP (2) EP2682395A1 (enExample)
JP (1) JP6401156B2 (enExample)
CN (1) CN104520304B (enExample)
CA (1) CA2878339A1 (enExample)
ES (1) ES2607183T3 (enExample)
IN (1) IN2015MN00068A (enExample)
MX (1) MX2015000056A (enExample)
PT (1) PT2870164T (enExample)
WO (1) WO2014006130A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190031615A1 (en) * 2016-01-15 2019-01-31 Laboratorios Del Dr. Esteve S.A. 3-ethyl-3-phenylazepane derivatives having multimodal activity against pain
WO2020127735A1 (en) * 2018-12-20 2020-06-25 Intervet International B.V. New methods of producing (2-amino-4-[6-(4-fluorophenyl)-2-[(4-methyl-1-piperazinyl)methyl]imidazo[2,1-b]thiazol-5-yl]-pyrimidine
JP2024544036A (ja) * 2021-11-29 2024-11-26 オーシャン ユニバーシティ オブ チャイナ イミダゾチアゾール誘導体およびその製造方法と使用
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265898A (en) * 1978-05-31 1981-05-05 Bayer Aktiengesellschaft Imidazo[2,1-b]-[1,3,4]-thiadiazole compounds, composition and their medicinal use
CN101277965A (zh) * 2005-08-04 2008-10-01 西特里斯药业公司 作为SIRTUIN调节化合物的咪唑并[2,1-b]噻唑衍生物
CN101855230A (zh) * 2007-10-23 2010-10-06 埃斯特韦博士实验室股份公司 用于制备6-取代的咪唑并[2，1-b]噻唑-5-磺酰卤的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621126A5 (enExample) 1974-02-07 1981-01-15 Plantex Ltd
DE3329621A1 (de) 1983-08-17 1985-02-28 Bayer Ag, 5090 Leverkusen Aminoalkyl-imidazothiadiazol-alkencarbonsaeureamide, neue zwischenprodukte zu ihrer herstellung, ihre herstellung und ihre verwendung in arzneimitteln
US7229480B2 (en) 2004-02-13 2007-06-12 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
AU2005276590B2 (en) * 2004-08-27 2011-05-19 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
EP1634873A1 (en) 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
US20060156484A1 (en) 2005-01-14 2006-07-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
AU2006278504B2 (en) 2005-08-04 2013-01-17 Sirtris Pharmaceuticals, Inc. Imidazopyridine derivatives as sirtuin modulating agents
EP1829869A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. 4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands
EP1847542A1 (en) 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
EP1982714A1 (en) * 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Pyrano-pyrazole-amines
WO2008144767A1 (en) 2007-05-21 2008-11-27 Sgx Pharmaceuticals, Inc. Heterocyclic kinase modulators
SI2193133T1 (sl) 2007-09-27 2015-12-31 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Imidazolotiadiazoli za uporabo kot zaviralci protein-kinaze
EP2070933A1 (en) 2007-12-07 2009-06-17 Laboratorios del Dr. Esteve S.A. Tricyclic triazolic compounds
EP2395003A1 (en) * 2010-05-27 2011-12-14 Laboratorios Del. Dr. Esteve, S.A. Pyrazole compounds as sigma receptor inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265898A (en) * 1978-05-31 1981-05-05 Bayer Aktiengesellschaft Imidazo[2,1-b]-[1,3,4]-thiadiazole compounds, composition and their medicinal use
CN101277965A (zh) * 2005-08-04 2008-10-01 西特里斯药业公司 作为SIRTUIN调节化合物的咪唑并[2,1-b]噻唑衍生物
CN101855230A (zh) * 2007-10-23 2010-10-06 埃斯特韦博士实验室股份公司 用于制备6-取代的咪唑并[2，1-b]噻唑-5-磺酰卤的方法

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"5-Arylazoimidazo[2, 1-b]-1, 3, 4-Thiadiazoles-NewDichroic T-Dyes For LCD";A. V. Ivashchenko等，;《Molecular Crystals and Liquid Crystals》;20061219;第145卷;第25-29页 *
"Bridgehead nitrogen heterocycles: facile synthesis of imidazo[2,1-b]-1,3,4-thiadiazoles using hypervalent iodine";Jag Mohan等，;《Journal of the Chinese Chemical Society》;19941231;第41卷(第5期);第617-619页 *
"Bridgehead nitrogen heterocyclic systems: facile synthesis and antimicrobial activity of imidazo[2,1-b]-1,3,4-thiadiazoles and thiadiazolo[2,3:2,1]imidazo[4,5-b]quinoxaline";Jag Mohan等，;《Indian Journal of Heterocyclic Chemistry》;19991231;第9卷;第143-146页 *
"Condensed bridgehead nitrogen heterocyclic systems. Facile synthesis and antimicrobial activity of imidazo[2,1-b]-1,3,4-thiadiazoles";Jag Mohan等，;《Indian Journal of Heterocyclic Chemistry》;20031231;第13卷;第101-104页 *
"Heterocyclic systems containing a bridge-head nitrogen atom: reactions of 2-aminothiadiazoles with a-haloketones and ketones in the presence of NBS";Mohan Jag等，;《Indian Journal of Chemistry》;19890630;第28B卷;第500-502页 *
"Influence of Chemical Structure on the Mesomorphic Behaviour of 3,5-Disubstituted 1,2,4-Oxadiazoles";S. Torgova等，;《Brazilian Journal of Physics》;20020630;第32卷(第2B期);第593-601页 *
"Mannich bases and novel benzothiazole derivatives of imidazo[2,1-b][1,3,4]thiadiazoles and their biological evaluation";Vinayak S. Hegde等，;《Journal of Sulfur Chemistry》;20070201;第27卷(第6期);第553-569页 *
"STN检索报告";王婷婷，;《STN》;20120416;第1-51页 *
"Synthesis and biological activity of anticoccidial agents: 5,6-Diarylimidazo[2,1-b][1,3]thiazoles";Andrew Scribner等，;《Bioorganic & Medicinal Chemistry Letters》;20080822;第18卷;第5263-5267页 *
"Synthesis and evaluation of antitubercular activity of imidazo[2,1-b][1,3,4]thiadiazole derivatives";Gundurao Kolavi等，;《Bioorganic & Medicinal Chemistry》;20060106;第14卷;第3069-3080页 *
"Synthesis of 2,6-Disubstituted Imidazo[2,1-b][1,3,4]thiadiazoles through Cyclization and Suzuki-Miyaura Cross-Coupling Reactions";Chloe Copin等，;《Eur. J. Org. Chem.》;20120423;第3079-3083页 *
"Synthesis of Imidazo[2,1-b]-1,3,4-thiadiazoles in DABCO as an Efficient and Recyclable Catalyst";Kamleshwar Tiwari等，;《Synthetic Communications》;20120110;第42卷;第3021-3030页 *

Also Published As

Publication number Publication date
JP2015521994A (ja) 2015-08-03
CA2878339A1 (en) 2014-01-09
EP2682395A1 (en) 2014-01-08
PT2870164T (pt) 2016-12-21
WO2014006130A1 (en) 2014-01-09
MX2015000056A (es) 2015-07-17
EP2870164B1 (en) 2016-09-14
CN104520304A (zh) 2015-04-15
IN2015MN00068A (enExample) 2015-10-16
ES2607183T3 (es) 2017-03-29
US9617281B2 (en) 2017-04-11
US20150166574A1 (en) 2015-06-18
JP6401156B2 (ja) 2018-10-03
HK1210149A1 (en) 2016-04-15
EP2870164A1 (en) 2015-05-13

Similar Documents

Publication Publication Date Title
TWI649325B (zh) 用於治療囊狀纖維化之新穎化合物及其醫藥組合物
CN104520304B (zh) 咪唑并[2，1‑b]噻唑衍生物、其制备及作为药物的用途
CN104903326B (zh) 被取代的吡唑并[3,4‑D]嘧啶化合物、其制备及作为σ受体配体的用途
EP2870145B1 (en) Indene derivatives, their preparation and use as medicaments
JP6124154B2 (ja) 置換ピラゾロ［１，５−ａ］ピリジン、その製造方法及び薬剤としての使用
EP2986616B1 (en) Tricyclic triazolic compounds as sigma receptors ligans
HK1210149B (en) Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments
HK1211570B (en) Indene derivatives, their preparation and use as medicaments
HK1215248B (en) Substituted pyrazolo[3,4-d]pyrimidine compounds, their preparation and use as sigma receptors ligands
HK1205504B (en) Substituted pyrazolo[1,5-a]pyridines, their preparation and use as medicaments
HK1221226B (en) Tricyclic triazolic compounds as sigma receptors ligans

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: Barcelona

Patentee after: Ethiway Pharmaceutical Co., Ltd.

Address before: Barcelona

Patentee before: Esteve Labor Dr.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170222

Termination date: 20210704